GSK|GSK plc|Price:50.575|Chg%:0.17

More Details of GSK plc Company

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

GSK plc Info



Ticker SymbolGSK

Company nameGSK plc

IPO dateMay 22, 1972

CEOWaterhouse (Deborah)

Number of employees68629

Security typeDepository Receipt

Fiscal year-endMay 22

Address980 Great West Road

CityBRENTFORD

Stock exchangeNASDAQ OMX NASDAQ Basic NYSE

CountryUnited Kingdom

Postal codeTW8 9GS

Phone442080475000

Websitehttps://www.gsk.com/

Ticker SymbolGSK

IPO dateMay 22, 1972

CEOWaterhouse (Deborah)

Company Executives of GSK plc



Name

Name/Position

Position

Shareholding

Change

Dr. Hal V. Barron, M.D.

Non-Executive Director

602.15K

+0.00%

Ms. Shobie Ramakrishnan

Chief Digital and Technology Officer

514.11K

+0.12%

Mr. Charles A. (Charlie) Bancroft

Senior Independent Non-Executive Director

41.23K

+0.76%

Ms. Elizabeth McKee (Liz) Anderson

Independent Non-Executive Director

3.45K

+0.75%

Dr. Jeannie Lee

Independent Non-Executive Director and Scientific & Medical Expert

2.00K

+0.70%

Mr. David S. Redfern

President - Corporate Development

--

Ms. Victoria Anne Whyte

Company Secretary

--

Mr. Phil C. Thomson

President - Global Affairs

--

Dame Emma N. Walmsley

Chief Executive Officer, Executive Director

--

Mr. Luke Miels

Chief Executive Officer - Designate, Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Hal V. Barron, M.D.

Non-Executive Director

602.15K

+0.00%

Ms. Shobie Ramakrishnan

Chief Digital and Technology Officer

514.11K

+0.12%

Mr. Charles A. (Charlie) Bancroft

Senior Independent Non-Executive Director

41.23K

+0.76%

Ms. Elizabeth McKee (Liz) Anderson

Independent Non-Executive Director

3.45K

+0.75%

Dr. Jeannie Lee

Independent Non-Executive Director and Scientific & Medical Expert

2.00K

+0.70%

Mr. David S. Redfern

President - Corporate Development

--

Revenue Breakdown

Currency: USDUpdated: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

HIV

10.12B

23.53%

Respiratory

9.31B

21.64%

Immuno-inflammation

5.02B

11.66%

Shingles

4.69B

10.89%

Established Vaccines

4.11B

9.55%

Other

9.78B

22.73%

By RegionUSD

Name

Revenue

Proportion

US

22.20B

51.61%

Rest of world

10.90B

25.33%

Europe

9.92B

23.06%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

HIV

10.12B

23.53%

Respiratory

9.31B

21.64%

Immuno-inflammation

5.02B

11.66%

Shingles

4.69B

10.89%

Established Vaccines

4.11B

9.55%

Other

9.78B

22.73%

Shareholding Stats

Updated: Thu, May 7

Shareholders

Shareholder Types

Shareholders

Proportion

Dodge & Cox

3.38%

Fidelity Management & Research Company LLC

2.81%

Fisher Investments

1.70%

PRIMECAP Management Company

1.24%

JTC Employer Solutions Trusteee Ltd

0.71%

Other

90.16%

Shareholders

Proportion

Dodge & Cox

3.38%

Fidelity Management & Research Company LLC

2.81%

Fisher Investments

1.70%

PRIMECAP Management Company

1.24%

JTC Employer Solutions Trusteee Ltd

0.71%

Other

90.16%

Shareholder Types

Shareholders

Proportion

Investment Advisor

9.05%

Investment Advisor/Hedge Fund

8.17%

Research Firm

1.01%

Hedge Fund

0.92%

Pension Fund

0.13%

Bank and Trust

0.10%

Individual Investor

0.06%

Family Office

0.03%

Family Office

0.02%

Other

80.52%

Institutional Shareholding



Updated: Wed, Apr 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q1

1585

393.46M

19.40%

-23.49M

2025Q4

1508

391.56M

19.21%

-21.81M

2025Q3

1474

388.63M

19.14%

-11.70M

2025Q2

1478

378.08M

18.54%

+5.70M

2025Q1

1494

378.46M

18.50%

+5.08M

2024Q4

1481

355.06M

17.14%

+27.38M

2024Q3

1472

319.97M

15.44%

-30.07M

2024Q2

1585

322.06M

15.54%

-29.11M

2024Q1

1617

318.91M

15.39%

-23.52M

2023Q4

1614

299.81M

14.57%

-35.71M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Dodge & Cox

68.52M

3.37%

-9.89M

-12.61%

Dec 31, 2025

Fidelity Management & Research Company LLC

56.97M

2.81%

+1.14M

+2.04%

Dec 31, 2025

Fisher Investments

33.20M

1.64%

+968.37K

+3.00%

Dec 31, 2025

PRIMECAP Management Company

25.13M

1.24%

-636.79K

-2.47%

Dec 31, 2025

JTC Employer Solutions Trusteee Ltd

14.43M

0.71%

-169.18K

-1.16%

Dec 31, 2025

Wellington Management Company, LLP

12.56M

0.62%

+9.14M

+267.14%

Dec 31, 2025

Acadian Asset Management LLC

8.96M

0.44%

+6.18M

+221.47%

Dec 31, 2025

Fidelity Institutional Asset Management

8.15M

0.4%

+179.23K

+2.25%

Dec 31, 2025

Holocene Advisors, LP

8.12M

0.4%

+1.02M

+14.31%

Dec 31, 2025

T. Rowe Price International Ltd

7.89M

0.39%

-56.47K

-0.71%

Dec 31, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

VanEck Pharmaceutical ETF

10.83%

The Opal International Dividend Income ETF

4.41%

Sound Equity Dividend Income ETF

3.97%

Keating Active ETF

3.88%

USCF Dividend Income Fund

3.83%

Brandes International ETF

2.87%

Altrius Global Dividend ETF

2.58%

Fidelity Blue Chip Value ETF

1.6%

Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF

1.17%

Avantis International Large Cap Value ETF

1.02%

VanEck Pharmaceutical ETF

Proportion10.83%

The Opal International Dividend Income ETF

Proportion4.41%

Sound Equity Dividend Income ETF

Proportion3.97%

Keating Active ETF

Proportion3.88%

USCF Dividend Income Fund

Proportion3.83%

Brandes International ETF

Proportion2.87%

Altrius Global Dividend ETF

Proportion2.58%

Fidelity Blue Chip Value ETF

Proportion1.6%

Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF

Proportion1.17%

Avantis International Large Cap Value ETF

Proportion1.02%

Dividend



A total of 15.69B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

May 04, 2026

GSK.NB Approximate interim Cash Dividend of gross USD 0.461074 paid on Jul 09, 2026 going ex on May 15, 2026

May 15, 2026

Jul 09, 2026

May 15, 2026

Apr 29, 2026

GSK.NB Interim Cash Dividend of gross paid on Jul 09, 2026 going ex on May 15, 2026

May 15, 2026

Jul 09, 2026

May 15, 2026

Feb 05, 2025

GSK.NB Interim Cash Dividend of gross USD 0.434774 paid on Jul 10, 2025 going ex on May 16, 2025

May 16, 2025

Jul 10, 2025

May 16, 2025

Feb 05, 2025

GSK.NB Interim Cash Dividend of gross USD 0.42996 paid on Oct 09, 2025 going ex on Aug 15, 2025

Aug 15, 2025

Oct 09, 2025

Aug 15, 2025

Feb 05, 2025

GSK.NB Approximate final Cash Dividend of gross USD 0.417088 paid on Jan 08, 2026 going ex on Nov 14, 2025

Nov 14, 2025

Jan 08, 2026

Nov 14, 2025

Feb 05, 2025

GSK.NB Interim Cash Dividend of gross USD 0.407568 paid on Apr 10, 2025 going ex on Feb 21, 2025

Feb 21, 2025

Apr 10, 2025

Feb 21, 2025

Feb 05, 2025

GSK.NB Approximate interim Cash Dividend of gross paid on Apr 09, 2026 going ex on Feb 20, 2026

Feb 20, 2026

Apr 09, 2026

Feb 20, 2026

Oct 30, 2024

GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024

Nov 15, 2024

Jan 09, 2025

Nov 15, 2024

Jul 31, 2024

GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Oct 10, 2024

Aug 16, 2024

May 01, 2024

GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024

May 17, 2024

Jul 11, 2024

May 16, 2024

Stock Splits



Date

Ex-dividend Date

Type

Ratio

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Date

Ex-dividend Date

Type

Ratio

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4